Manzo Pharmaceuticals, Inc. engages in the provision of pharmaceutical preparations services. The company is headquartered in North York, Ontario. The company went IPO on 2001-07-11. The firm also develops its lactose intolerance product, for which it holds an exclusive patent license. The firm's primary products are dietary supplements, probiotics and natural remedies. The firm's subsidiary, Manzo Pharmaceuticals LLC (Manzo), is an alternative healthcare company with patents for a probiotic remedy for lactose intolerance. The firm also owns other products, including a remedy for babies suffering from colic and/or digestive gas. Manzo's Lacto-Freedom probiotic is a probiotic that aids in the digestion of lactose-containing foods, designed specifically for people with lactose sensitivity.
SUIC Worldwide Holdings Ltd 주요 수익원은 Internet of Things, Cloud Computing, Mobile Payments, Big Data, Blockchain and Artificial Intelligence이며, 최신 수익 발표에서 수익은 150,000입니다. 지역별로는 United States이 SUIC Worldwide Holdings Ltd의 주요 시장이며, 수익은 150,000입니다.
Exxsun Corp은 수익성이 있나요?
no, 최신 재무제표에 따르면 SUIC Worldwide Holdings Ltd의 순손실은 $0입니다.